Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

ARS Pharmaceuticals (SPRY) Assets Average (2021 - 2025)

Historic Assets Average for ARS Pharmaceuticals (SPRY) over the last 5 years, with Q3 2025 value amounting to $343.1 million.

  • ARS Pharmaceuticals' Assets Average rose 5612.52% to $343.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $343.1 million, marking a year-over-year increase of 5612.52%. This contributed to the annual value of $292.2 million for FY2024, which is 1354.74% up from last year.
  • As of Q3 2025, ARS Pharmaceuticals' Assets Average stood at $343.1 million, which was up 5612.52% from $320.4 million recorded in Q2 2025.
  • ARS Pharmaceuticals' Assets Average's 5-year high stood at $374.6 million during Q2 2021, with a 5-year trough of $187.0 million in Q1 2022.
  • Over the past 5 years, ARS Pharmaceuticals' median Assets Average value was $276.3 million (recorded in 2022), while the average stood at $277.1 million.
  • Its Assets Average has fluctuated over the past 5 years, first plummeted by 2146.85% in 2022, then soared by 5612.52% in 2025.
  • ARS Pharmaceuticals' Assets Average (Quarter) stood at $207.0 million in 2021, then surged by 33.45% to $276.2 million in 2022, then decreased by 12.81% to $240.9 million in 2023, then grew by 18.06% to $284.4 million in 2024, then increased by 20.66% to $343.1 million in 2025.
  • Its last three reported values are $343.1 million in Q3 2025, $320.4 million for Q2 2025, and $339.2 million during Q1 2025.